Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

Michael Koren(Walter Reed Army Institute of Research), Kayvon Modjarrad(Pfizer (United States)), Rafael De La Barrera(Walter Reed Army Institute of Research), Jack Hutter, Sheila A. Peel(Henry M. Jackson Foundation), Mihret F. Amare(Henry M. Jackson Foundation), Nelson L. Michael(Walter Reed Army Institute of Research), Margaret C. Costanzo(Henry M. Jackson Foundation), Vincent Dussupt(Henry M. Jackson Foundation), Gregory D. Gromowski(Walter Reed Army Institute of Research), Tsedal Mebrahtu(Henry M. Jackson Foundation), Stephen J. Thomas(Global Viral), Shelly J. Krebs(Henry M. Jackson Foundation), Melinda Hamer, Trevor A. Crowell(Henry M. Jackson Foundation), Janice M. Darden(Henry M. Jackson Foundation), Kenneth H. Eckels(Walter Reed Army Institute of Research), Kristin T Mills(Walter Reed Army Institute of Research), Merlin L. Robb(University of Maryland, Baltimore), Richard G. Jarman(Walter Reed Army Institute of Research), Nathanial K. Copeland(Walter Reed Army Institute of Research), Erica L Sondergaard(Walter Reed Army Institute of Research), Paul B. Keiser(Walter Reed Army Institute of Research), Justin M Curley(Walter Reed Army Institute of Research), Anais Valencia-Ruiz(Henry M. Jackson Foundation), Christine Lee(Walter Reed Army Institute of Research), Gina Donofrio(Henry M. Jackson Foundation), Leyi Lin(Walter Reed Army Institute of Research), O.S. Adedeji(Emmes (United States))
The Lancet Infectious Diseases
June 27, 2023
Cited by 23


Related Papers